<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717219</url>
  </required_header>
  <id_info>
    <org_study_id>NL72973.091.20</org_study_id>
    <nct_id>NCT04717219</nct_id>
  </id_info>
  <brief_title>Myeloid Cells in Aortic Valve Stenosis</brief_title>
  <acronym>MIRACLE</acronym>
  <official_title>Myeloid Cell Reprogramming in Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators plan to characterize systemic inflammation and circulating immune cells in&#xD;
      participants with moderate and severe calcific aortic valve disease and matched healthy&#xD;
      controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcific aortic valve disease (CAVD) is the most common type of valvular heart disease in the&#xD;
      Western world. Due to the aging of the population, the impact of this disorder is expected to&#xD;
      further increase in the next decades. The underlying pathophysiology remains incompletely&#xD;
      defined and there are currently no effective medical treatments capable of altering its&#xD;
      course, identifying a major unmet need in this growing population of patients.&#xD;
&#xD;
      Based on the similarities between CAVD and atherosclerosis in pathophysiology and shared risk&#xD;
      factors, it is now hypothesized that activation of the innate immune system contributes to&#xD;
      the development of CAVD. Therefore, the investigators will perform an observational study to&#xD;
      assess the role of activation of the innate immune system in CAVD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory phenotype of circulating immune cells.</measure>
    <time_frame>2 years</time_frame>
    <description>The inflammatory phenotype of circulating immune cells will be measured by determining the cytokine production capacity after stimulation with relevant stimuli.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Severe CAVD with atherosclerosis</arm_group_label>
    <description>Participants with severe CAVD and significant atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe CAVS without atherosclerosis</arm_group_label>
    <description>Participants with severe CAVD without significant atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate CAVD with atherosclerosis</arm_group_label>
    <description>Participants with moderate CAVD and significant atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate CAVD without atherosclerosis</arm_group_label>
    <description>Participants with moderate CAVD without significant atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy controls without CAVD and without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication and overt heart failure (NYHA class III/IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls with bicuspid aortic valve stenosis</arm_group_label>
    <description>Controls with bicuspid aortic valve stenosis, without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood drawing</intervention_name>
    <description>Blood will be drawn after inclusion of the participants.</description>
    <arm_group_label>Controls with bicuspid aortic valve stenosis</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Moderate CAVD with atherosclerosis</arm_group_label>
    <arm_group_label>Moderate CAVD without atherosclerosis</arm_group_label>
    <arm_group_label>Severe CAVD with atherosclerosis</arm_group_label>
    <arm_group_label>Severe CAVS without atherosclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who present themselves or are already known at the department of cardiology or&#xD;
        cardiothoracic surgery with the diagnosis of moderate or severe aortic valve stenosis as&#xD;
        defined by transthoracic echocardiography according to the 2017 ESC/EACTS guidelines for&#xD;
        the management of valvular heart disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Moderate to severe degenerative aortic valve stenosis as defined by transthoracic&#xD;
             echocardiography according to the 2017 ESC/EACTS guidelines for the management of&#xD;
             valvular heart disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Auto-inflammatory or auto-immune diseases&#xD;
&#xD;
          -  Use of anti-inflammatory drugs&#xD;
&#xD;
          -  Vaccination less than one month before inclusion&#xD;
&#xD;
          -  Bone marrow transplantation in medical history&#xD;
&#xD;
          -  Active hematological disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels P. Riksen, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels P. Riksen, prof. dr.</last_name>
    <phone>+31-343618819</phone>
    <email>Niels.Riksen@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Riksen, MD, PhD</last_name>
      <phone>0031-24-3618819</phone>
      <email>niels.riksen@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Niels Riksen</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>calcific aortic valve disease</keyword>
  <keyword>valvular heart disease</keyword>
  <keyword>inflammation</keyword>
  <keyword>innate immune cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

